Pancreatic cancer has long been a disease of cruel timing — lethal not because it is untreatable, but because it is almost never found in time. Researchers at Kanazawa University have developed a blood test called Panregza that detects early-stage pancreatic cancer in 9 of 10 cases by reading gene expression patterns in immune cells, compared to just 1 of 10 for the standard CA19-9 marker. Where early detection leads to surgery, survival rates climb dramatically — to 100% at stage 0 in Kanazawa's own data. The question now is whether this signal, so clear in the laboratory, can hold its promis
Blood Gene Test Shows 90% Detection Rate for Early-Stage Pancreatic Cancer
Pancreatic cancer remains highly lethal with only 8.5% five-year survival in Japan, making early detection critical for patient outcomes.
The cancer leaves a detectable fingerprint in blood long before symptoms appear
Mark
So this test catches 90% of early pancreatic cancers. That sounds like a breakthrough. But I'm wondering—how many people would you have to screen to find one actual case?
Mimi
That's the right question. Early-stage pancreatic cancer is rare, maybe 2 to 3 percent of all diagnoses. So you'd screen hundreds of people to find one. The test itself is accurate, but screening a whole population is a different problem.
Luke
And we should be clear about what this study actually shows. Ten patients with early-stage cancer. Ten. That's not a population study. It's a proof-of-concept. The specificity looks good—93% in their healthy comparison group—but we don't know how it performs in people with other pancreatic conditions, or in a real screening scenario.
Mark
The five-year survival rates at Kanazawa are remarkable though. 100% for stage 0, 74% for stage I. That's not a fluke, is it?
Mimi
No, that's real. But it's also a specialized center with expertise in early pancreatic cancer surgery. Those numbers reflect what's possible when you catch it early and have the surgical skill to remove it. Most hospitals don't have that capacity.
Luke
And those survival rates are from their own patient population. We don't have independent verification. The test itself is promising, but the leap from "this test detects early cancer" to "this test will improve survival in the general population" requires evidence we don't have yet.
Mark
What about the mechanism? Why does the blood test work better than CA19-9?
Mimi
The theory is that even tiny tumors change how immune cells in the blood behave—their gene expression patterns shift. The test picks up those shifts. CA19-9 is a protein marker, and it doesn't rise until the tumor is larger.
Luke
But that's still partly theoretical. They know the gene expression patterns differ, and they know it correlates with cancer presence. The exact biological mechanism—how the tumor influences those immune cells—isn't fully mapped.
Mark
So what's the next step?
Mimi
Larger validation studies. Testing in different populations. And then, if it holds up, figuring out how to use it clinically. Do you screen everyone? Only high-risk groups? That's not answered yet.
Luke
And cost. The test is already being marketed, which is interesting. But we don't know the price, whether insurance covers it, or whether hospitals will actually adopt it. The science is one thing. The real-world implementation is another.
O Pulso
- Pancreatic cancer kills 91.5% of Japanese patients within five years — not because treatment fails, but because the disease is almost always found too late to treat.
- A new blood test from Kanazawa University detected 9 of 10 early-stage pancreatic cancers, while the standard CA19-9 marker caught only 1 — a ninefold difference that could redefine what early diagnosis means.
- The test works by detecting subtle shifts in immune cell gene expression triggered by even tiny tumors, a biological fingerprint that appears long before conventional markers register any alarm.
- Panregza is already commercially available through Cubix Inc., giving the discovery an unusual head start on the long road from research finding to clinical routine.
- The critical unknown remains scale — early-stage pancreatic cancer is vanishingly rare in the general population, and proving the test's reliability will require validation across thousands of people in diverse settings.
Pancreatic cancer has long been a disease of cruel timing — lethal not because it is untreatable, but because it is almost never found in time. Researchers at Kanazawa University have developed a blood test called Panregza that detects early-stage pancreatic cancer in 9 of 10 cases by reading gene expression patterns in immune cells, compared to just 1 of 10 for the standard CA19-9 marker. Where early detection leads to surgery, survival rates climb dramatically — to 100% at stage 0 in Kanazawa's own data. The question now is whether this signal, so clear in the laboratory, can hold its promise across the wider, noisier world of population screening.
Pancreatic cancer kills with a particular cruelty: not because it resists treatment, but because it hides. In Japan, only 8.5% of patients survive five years after diagnosis, and early-stage disease accounts for just 2 to 3% of all cases — not because it is uncommon, but because it is nearly undetectable until it has already spread beyond the reach of surgery.
Researchers at Kanazawa University, led by Dr. Yamashita, believe they have found a way to change that. Their blood test, Panregza, analyzes gene expression patterns in blood cells rather than searching for tumor proteins. Studying ten patients with stage 0 or stage I pancreatic cancer alongside 104 healthy individuals, the team used a panel of 56 gene probes to look for early signals of disease. The results were stark: the gene expression test identified 9 of the 10 early-stage cancers. The standard CA19-9 marker found only 1.
The stakes behind that disparity are enormous. At Kanazawa University Hospital, patients with stage 0 disease who received timely surgery achieved a 100% five-year survival rate. Stage I patients reached 74.4%. Pancreatic cancer's grim prognosis, the data suggests, is not a biological inevitability — it is a consequence of late diagnosis.
The mechanism is not yet fully understood. Immune cells in peripheral blood appear to alter their gene expression patterns in response to even small tumors, leaving a detectable fingerprint before CA19-9 levels rise or symptoms emerge. Earlier research had shown this effect in advanced disease; this study demonstrates it holds in the earliest stages as well.
Panregza is already being marketed commercially by Cubix Inc., giving the research an unusual foothold in clinical reality. The combined test showed 60% sensitivity and 93.3% specificity in early-stage patients — a meaningful signal, though the harder test lies ahead. Validating performance across large, diverse populations — where early pancreatic cancer is rare and screening demands finding a handful of cases among thousands — will determine whether this promising result becomes a genuine turning point in one of medicine's most stubborn problems.
Pancreatic cancer kills with brutal efficiency. In Japan, only 8.5% of patients survive five years after diagnosis—a figure that has barely budged despite decades of medical progress. The disease's lethality stems from a single, cruel fact: by the time most people learn they have it, the cancer has already spread beyond the reach of surgery. Early-stage pancreatic cancer accounts for just 2 to 3 percent of all diagnosed cases, not because it is rare, but because it is nearly invisible until it is too late.
Researchers at Kanazawa University believe they may have found a way to change that calculus. A team led by Dr. Yamashita has developed a blood test that detects early-stage pancreatic cancer with 90% accuracy—a dramatic leap beyond the standard diagnostic marker currently in use. The test, called Panregza, works by analyzing gene expression patterns in blood cells rather than hunting for tumor proteins. The implications are substantial: if the test proves reliable across larger populations, it could catch pancreatic cancer years before symptoms appear, when surgery still offers a genuine chance at cure.
The research centered on a deceptively simple question: can changes in blood cell gene expression reveal the presence of pancreatic cancer before the tumor grows large enough to be detected by conventional means? Yamashita's group examined ten patients with stage 0 or stage I pancreatic cancer—representing just 4 percent of the 253 cases they studied—and compared their blood profiles to those of 104 healthy individuals. Using a panel of 56 gene probes, the researchers looked for patterns that might signal early disease. The results were striking. The gene expression test identified 9 of the 10 early-stage cancers. The standard tumor marker, CA19-9, found only 1.
Why the disparity matters becomes clear when you consider what early detection actually achieves. At Kanazawa University Hospital's pancreatic cancer center, patients with stage 0 disease who received early surgical intervention achieved a 100% five-year survival rate. Stage I patients reached 74.4%. These numbers stand in sharp contrast to the national average and underscore a hard truth: pancreatic cancer's poor prognosis is not inevitable. It is a consequence of late diagnosis. Catch it early, remove it surgically, and survival becomes possible.
The mechanism behind the blood test's sensitivity remains partially mysterious. Most cells in peripheral blood are immune cells, and researchers theorize that pancreatic tumors—even tiny ones—alter the gene expression patterns of these immune cells through mechanisms not yet fully understood. Previous work had shown that such changes occur in advanced pancreatic cancer, where tumor burden is substantial. This new study demonstrates that the same gene expression shifts happen in stage 0 and stage I disease, when the tumor is small and CA19-9 levels remain normal. The cancer, in other words, leaves a detectable fingerprint in the blood long before it announces itself through conventional markers.
The Panregza test is not theoretical. It is already being marketed by Cubix Inc., a company commercializing the diagnostic kit. The combined test—gene expression analysis plus CA19-9—showed 60% sensitivity and 93.3% specificity in this early-stage population, meaning it correctly identified most cancers while generating relatively few false alarms. What remains unknown is whether the test will perform as well in the general population, where early-stage pancreatic cancer is rare and screening would require testing thousands of people to find a handful of cases. The path from promising laboratory results to routine clinical screening is long, and validation in larger, more diverse populations will be essential before widespread adoption.
For now, the research offers something pancreatic cancer patients have lacked: a concrete reason to believe that earlier detection is possible. The disease remains formidable, but the window of opportunity—the moment when surgery can still save a life—may finally be within reach.
Citações Notáveis
Early-stage pancreatic cancer accounts for only 2–3% of all diagnosed cases because of the difficulty of early detection— Kanazawa University research team
Gene expression analysis from peripheral whole blood is a highly effective method for detecting early-stage pancreatic cancer— Dr. Yamashita and colleagues, Kanazawa University
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine